Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (368)	8/31/2005 10:32:27 PM
From: Biomaven	Read Replies (1) \| Respond to of 510

tuck, Yes I did follow the discussion re ELISA - it does seem likely that many tests would ultimately be done as an ELISA, particularly if only a few proteins are involved (as is the case with this interesting hepatocellular carcinoma discovery). But presumably they could still do fine if they get a royalty because the basis for which proteins to test for were discovered with a CIPH chip. I never did re-enter, but I keep watching to see if they come up with a convincing business model. Peter

To: tuck who wrote (368)	9/12/2005 8:35:16 PM
From: tuck	Read Replies (1) \| Respond to of 510

[Proteohistography--Direct Analysis of Tissue with High Sensitivity and High Spatial Resolution Using ProteinChip Technology.] >>J Histochem Cytochem. 2005 Sep 7; [Epub ahead of print] Proteohistography--Direct Analysis of Tissue with High Sensitivity and High Spatial Resolution Using ProteinChip Technology. Ernst G, Melle C, Schimmel B, Bleul A, von Eggeling F. Core Unit Chip Application (CUCA), Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Germany. On the proteomic level all tissues, tissue constituents or even single cells are heterogeneous, but the biological relevance of this cannot be adequately investigated with any currently available technique. This is because the analysis of proteins of small tissue areas by any proteomic approach is limited by the number of required cells; increasing the number of cells only serves to lower the spatial resolution of expressed proteins. To enhance sensitivity and spatial resolution we developed Proteohistography (PHG). Laser microdissection was used to mark special areas of interest on tissue sections attached to glass slides. These areas were positioned under microscopic control directly on an affinity chromatographic ProteinChip Array so that cells were lysed and their released proteins bound on a spatially defined point. The ProteinChip((R)) System (SELDI-TOF-MS) allows to steer the laser to up to 215 distinct positions across the surface of the spot, enabling a high spatial resolution of measured protein profiles for the analyzed tissue area. Protein profiles of the single positions were visually plotted over the used tissue section to visualize proteohistologically distribution. Results show that the spatial distribution of detectable proteins could be used as Proteohistogram for a given tissue area. Consequently this procedure can provide additionally information to both a MALDI-based approach and immunohistochemistry, as it is more sensitive, highly quantitative and no specific antibody is needed. Hence, proteomic heterogeneity can be visualized even if proteins are not known or identified.<< These guys aren't great at English, but interesting stuff. Cheers, Tuck